Emerging therapies for breast cancer

被引：54

作者：

Hu, Xichun ^{[1
,2
]}

Huang, Wei ^{[3
]}

Fan, Minhao ^{[4
]}

机构：

[1] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China

[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China

[3] Roche Prod Dev Asia Pacific, 5F,Tower C,Parkview Green 9,Dongdaqiao Rd, Beijing 100020, Peoples R China

[4] Hutchison MediPharma Ltd, Bldg 4 917 Halei Rd Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2017年 / 10卷

关键词：

Breast cancer; CDK4/6; inhibitors; SERD; PD1 and PD-L1 antibodies; PARP inhibitors; Fulvestrant; ADC; Nab-paclitaxel; TUMOR-INFILTRATING LYMPHOCYTES; KINASE; 4/6; INHIBITOR; EPITHELIAL-MESENCHYMAL TRANSITION; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; ESTROGEN-RECEPTOR-ALPHA; SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; FULVESTRANT; 500; MG; DNA-REPAIR DEFECT;

D O I：

10.1186/s13045-017-0466-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.

引用

页数：17

共 177 条

[11] Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse [J].

Bates, Gaynor J. ;

Fox, Stephen B. ;

Han, Cheng ;

Leek, Russell D. ;

Garcia, Jose F. ;

Harris, Adrian L. ;

Banham, Alison H. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5373-5380

[12] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer [J].

Bergh, Jonas ;

Jonsson, Per-Ebbe ;

Lidbrink, Elisabet Kerstin ;

Trudeau, Maureen ;

Eiermann, Wolfgang ;

Brattstrom, Daniel ;

Lindemann, Justin P. O. ;

Wiklund, Fredrik ;

Henriksson, Roger .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1919-1925

[13] Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness [J].

Bocca, Claudia ;

Ievolella, Monica ;

Autelli, Riccardo ;

Motta, Manuela ;

Mosso, Luciano ;

Torchio, Bruno ;

Bozzo, Francesca ;

Cannito, Stefania ;

Paternostro, Claudia ;

Colombatto, Sebastiano ;

Parola, Maurizio ;

Miglietta, Antonella .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (02) :121-135

[14] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer [J].

Boyraz, Baris ;

Sendur, Mehmet A. N. ;

Aksoy, Sercan ;

Babacan, Taner ;

Roach, Emir C. ;

Kizilarslanoglu, Muhammet C. ;

Petekkaya, Ibrahim ;

Altundag, Kadri .

CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) :405-414

[15] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[16] Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival [J].

Brown, Scott D. ;

Warren, Rene L. ;

Gibb, Ewan A. ;

Martin, Spencer D. ;

Spinelli, John J. ;

Nelson, Brad H. ;

Holt, Robert A. .

GENOME RESEARCH, 2014, 24 (05) :743-750

[17] nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings [J].

Brufsky, Adam .

EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6

[18] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[19] Poly(APD-ribosyl)ation, a DNA damage-driven protein modification and regulator of genomic instability [J].

Bürkle, A .

CANCER LETTERS, 2001, 163 (01) :1-5

[20]

Callahan MK, 2014, J CLIN ONCOL, P32

← 1 2 3 4 5 6 7 8 9 10 →